Fatal Outcome of Pembrolizumab-Related Cytokine Release Syndrome in a Patient With Concurrent Parainfluenza Infection
Pembrolizumab improves response and survival in triple-negative breast cancer; however, severe immune-related adverse effects (irAEs) are concerning. We present a case of a patient with triple-negative breast cancer on neoadjuvant pembrolizumab who developed high fever and chills after the seventh c...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American College of Physicians
2025-02-01
|
| Series: | Annals of Internal Medicine: Clinical Cases |
| Online Access: | https://www.acpjournals.org/doi/10.7326/aimcc.2023.1217 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Pembrolizumab improves response and survival in triple-negative breast cancer; however, severe immune-related adverse effects (irAEs) are concerning. We present a case of a patient with triple-negative breast cancer on neoadjuvant pembrolizumab who developed high fever and chills after the seventh cycle. Rapid deterioration occurred, leading to multiple-organ failure. Parainfluenza virus was identified in various cultures, and interleukin-6 levels were disproportionately elevated (79 014 ng/L), resulting in the diagnosis of cytokine release syndrome. This case underscores the need for vigilant monitoring and care when parainfluenza infection coincides with immune checkpoint inhibitors due to potentiated immune responses and fatal complications. |
|---|---|
| ISSN: | 2767-7664 |